Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
about
Clozapine Monitoring in Clinical Practice: Beyond the Mandatory RequirementSystematic Review of Clozapine Cardiotoxicity.Unrecognized clozapine-related constipation leading to fatal intra-abdominal sepsis - a case report.Spatiotemporal Mapping Techniques Show Clozapine Impairs Neurogenic and Myogenic Patterns of Activity in the Colon of the Rabbit in a Dose-Dependent MannerThe Porirua Protocol in the Treatment of Clozapine-Induced Gastrointestinal Hypomotility and Constipation: A Pre- and Post-Treatment Study.Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports.Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in IcelandEstablishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis.Classics in chemical neuroscience: clozapine.Gene-expression analysis of clozapine treatment in whole blood of patients with psychosisOpening Pandora's box in the UK: a hypothetical pharmacogenetic test for clozapine.A state-wide quality improvement system utilising nurse-led clinics for clozapine management.The impact of psychopharmacology on contemporary clinical psychiatry.Hepatotoxicity induced by clozapine: a case report and review of literature.Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis.Clozapine-induced myocarditis, a widely overlooked adverse reaction.Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland.Clozapine-Induced Gastrointestinal Hypomotility: A 22-Year Bi-National Pharmacovigilance Study of Serious or Fatal 'Slow Gut' Reactions, and Comparison with International Drug Safety Advice.Worldwide Differences in Regulations of Clozapine Use.Multivalent approaches and beyond: novel tools for the investigation of dopamine D2 receptor pharmacology.What Is the Place of Clozapine in the Treatment of Early Psychosis in Canada?Pharmacological treatment for antipsychotic-related constipation.Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management.Dyspepsia and constipation in patients with schizophrenia spectrum disorders.Fusing Sensor Paradigms to Acquire Chemical Information: An Integrative Role for Smart Biopolymeric Hydrogels.Clozapine-associated cardiac dysfunction during a gastroenteritis outbreak.The Binding Effect of Proteins on Medications and Its Impact on Electrochemical Sensing: Antipsychotic Clozapine as a Case Study.Clozapine-associated pneumonia and respiratory arrest secondary to severe constipation.Clozapine-induced myocarditis may be associated with rapid titration: A case report verified with autopsy.Continuation with clozapine after eosinophilia: a case report.Clozapine in primary care.Two cases of high serum clozapine concentrations occurring during inflammation in Chinese patients.Clozapine and Gastrointestinal Hypomotility.The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder.Multiple physical healthcare needs among outpatients with schizophrenia: findings from a health examination study.Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population.Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations.Prescribers fear as a major side-effect of clozapine.Effectiveness and safety of rapid clozapine titration in schizophrenia.Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.
P2860
Q28075904-294B180C-A7D6-4D7C-8C69-CB82FDF7133FQ30250192-3B00C739-FED7-4D7E-84A9-47CB9EBC32AFQ33166261-CF2DAC95-F55A-425D-B527-8B4034B5A417Q33593376-4E8FA8E7-9AAE-4327-AF39-B6EE04529D42Q34544343-E002E360-C34A-4444-8549-EBE2F172B575Q36122601-30B6D028-5968-4269-BCBA-3C8C4BFF0F57Q36220897-01E9BC41-581A-4BE5-AEB4-C511CBAEB681Q36605131-9C2B6EEA-3F7D-4E32-ADB9-245E3B190EEFQ37025878-426DA1DE-1EC1-4492-ADB2-8C017BD0CC4AQ37229987-C248C182-22F1-4600-A516-F1BA8F5C6EDDQ38162870-954608A1-1556-4565-B632-5F0325EFEAFAQ38210463-7C7A5D4E-32A1-4F69-83EB-A34BF9FBCECAQ38243753-6011C0EE-AD4F-4C5E-A0CC-40B0757C1D5AQ38248273-34F143EF-64B7-4433-8C16-D7A31039A495Q38271339-F03170F8-EBE8-403D-85F4-CBDB7FEF2F34Q38417079-D3B51A56-9C1C-47DF-8144-1B232055E7CAQ38717462-4EAB8A36-7831-4624-9917-AB1A3A10069FQ38721556-D93B6A2F-4B7E-426D-A176-36F79A97C981Q38736547-1EBBBE4B-83BD-4B16-886E-42052BA9C11BQ38846984-5AABCB34-6EEB-4327-94D8-8005E1AA70B4Q38867008-2617441C-2892-455B-991D-97F5A26CF596Q39002818-7F99733E-948F-49AD-8979-8020EA332229Q40082921-F0D073E0-D741-4D81-AB0C-2098851C1C50Q40606375-F969CA53-3FB9-4869-858F-D4AE68199AC8Q41628681-2786F601-952C-4078-AA5E-56EDED709F15Q42350847-6F7E90A8-AD99-4F47-996F-B6FD34A444C5Q42366878-DAE06F18-EF96-4616-8BB5-1F3A3875373DQ44993408-F3EE0AAC-FDC0-4A42-9087-44F0346C0FB7Q46893940-66AE30F1-AAF5-40AC-8358-F36C7337E0EAQ47122840-481A2ED8-0DA1-4AE8-BF49-05903AA1E288Q47551390-D860996C-819C-485A-B653-4B58A2C25C22Q47558742-EE7523B8-A2B8-4D93-8A30-D7C356CAFA9EQ47565362-11A5B271-5844-4F43-93A3-C58D71178724Q47575822-A0FE9E17-3080-47A7-AE95-4069A09D8C43Q47725134-317350F9-0E6C-426A-BC5E-726136180EDAQ48026160-0BC72419-1207-4683-9A49-CA068809F15BQ50590340-D9B00863-3762-4CA0-81EF-6A64B4C67F00Q50642975-4CF742C2-2D86-4C15-99D7-B1F8D2654B8FQ54417865-CCCA7B6F-32CE-4F03-8A58-E721D21A962DQ55232340-9EAF4ACD-5F89-4A7D-B1CB-53278B91DED2
P2860
Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
@ast
Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
@en
Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
@nl
type
label
Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
@ast
Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
@en
Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
@nl
prefLabel
Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
@ast
Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
@en
Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
@nl
P2093
P356
P1476
Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
@en
P2093
Bert Bakker
Daniel van Dijk
Jan P A M Bogers
Peter F J Schulte
P304
P356
10.4088/JCP.11R06977
P577
2012-10-01T00:00:00Z